open access

Vol 58, No 2 (2007)
Original papers
Published online: 2007-03-13
Submitted: 2013-02-15
Get Citation

Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report

Beata Kos-Kudła, Anna Zemczak, Wanda Foltyn, Bogdan Marek, Janusz Strzelczyk, Aleksandra Telega, Wojciech Zajęcki, Tomasz Legaszewski, Beata Jurecka-Lubieniecka
Endokrynologia Polska 2007;58(2):123-129.

open access

Vol 58, No 2 (2007)
Original papers
Published online: 2007-03-13
Submitted: 2013-02-15

Abstract

Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and is important in monitoring the disease course and NET treatment.
Aim of the study: Usefulness of suppression test of CgA secretion with octreotide in diagnosis and predicting the therapy outcome in NET patients.
Material and methods: The study included 32 patients with NET of gastrointestinal tract, lung and of unknown origin. CgA level in blood plasma on fasting, before and 30, 60, 90 and 120 minutes after subcutaneous administration of 100 μg octreotide, was determined in all patients. The subjects were divided into two subgroups with relation to CgA level and to the results of somatostatin receptor scintigraphy (SRS).
Results: Statistically significant CgA decrease after octreotide administration in all study time points and positive results of SRS were found in the patients with the elevated CgA level. No statistically significant decrease of CgA level after octreotide was found in the group with normal CgA levels. In this group, 13 patients had a negative result of SRS, and somatostatin receptors expression was found in one patient. Tolerance of somatostatin analogs (SSA) therapy was very good.
Conclusions: Octreotide suppression test with CgA level assessment in NET patients is a simple, straightforward examination, providing information on the predicted response to the applied SSA and the data on initial clinical tolerance of those agents. This examination can also be a screening test useful in planning the treatment with SSA in patients with NET.

Abstract

Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and is important in monitoring the disease course and NET treatment.
Aim of the study: Usefulness of suppression test of CgA secretion with octreotide in diagnosis and predicting the therapy outcome in NET patients.
Material and methods: The study included 32 patients with NET of gastrointestinal tract, lung and of unknown origin. CgA level in blood plasma on fasting, before and 30, 60, 90 and 120 minutes after subcutaneous administration of 100 μg octreotide, was determined in all patients. The subjects were divided into two subgroups with relation to CgA level and to the results of somatostatin receptor scintigraphy (SRS).
Results: Statistically significant CgA decrease after octreotide administration in all study time points and positive results of SRS were found in the patients with the elevated CgA level. No statistically significant decrease of CgA level after octreotide was found in the group with normal CgA levels. In this group, 13 patients had a negative result of SRS, and somatostatin receptors expression was found in one patient. Tolerance of somatostatin analogs (SSA) therapy was very good.
Conclusions: Octreotide suppression test with CgA level assessment in NET patients is a simple, straightforward examination, providing information on the predicted response to the applied SSA and the data on initial clinical tolerance of those agents. This examination can also be a screening test useful in planning the treatment with SSA in patients with NET.
Get Citation

Keywords

neuroendocrine tumors; chromogranin A; octreotide test

About this article
Title

Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report

Journal

Endokrynologia Polska

Issue

Vol 58, No 2 (2007)

Pages

123-129

Published online

2007-03-13

Bibliographic record

Endokrynologia Polska 2007;58(2):123-129.

Keywords

neuroendocrine tumors
chromogranin A
octreotide test

Authors

Beata Kos-Kudła
Anna Zemczak
Wanda Foltyn
Bogdan Marek
Janusz Strzelczyk
Aleksandra Telega
Wojciech Zajęcki
Tomasz Legaszewski
Beata Jurecka-Lubieniecka

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl